Skip to main content

Table 1 Common alterations in phosphatidylinositol 3-kinase p110α isoform gene (PIK3CA), PIK3CB and phosphatase and tensin homologue deleted on chromosome 10 (PTEN) in cancer

From: Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment

Alteration Occurrence (%) References
PIK3CA mutations:
Breast 26% (1,559/6,110) [108]
Endometrium 24% (282/1,194) [108]
Penis 29% (8/28) [108, 109]
Urinary tract 20% (189/942) [108]
Large intestine 12% (779/6,710) [108]
Stomach 12% (96/824) [108]
Ovary 10% (163/1,590) [108]
Cervix 10% (25/256) [108]
PIK3CA amplifications:
Gastric 67% to 36% [110, 111]
Papillary thyroid cancer 53% (265/499) [112]
Head and neck 55% to 37% [113, 114]
Non-small cell lung cancer 31% [115]
Squamous cell carcinoma 59% (31/52) [116]
Cervical 70% to 44% [117, 118]
Ovarian 35% (54/152) [119]
Prostate 28% (9/32) [120]
Endometrial 12% to 15% [121, 122]
Breast 8% (8/92) [123]
Triple negative 31% [124]
Chronic lymphocitic leukemia 5% [125]
PIK3CB amplification:
Breast 5% [72]
Non-small cell lung cancer squamous cell carcinoma 56% [116]
PTEN loss of heterozygosity:
Glioblastoma 59% [126]
Prostate 15% to 70% [127130]
Breast 11% to 38% [131, 132]
Melanoma 33% (7/21) [133]
Gastric 47% (14/30) [111]
Uveal melanoma 76% to 39% [134]
PTEN mutation:
Endometrium 37% (690/1,860) [135]
Vulva 62% (5/8) [136]
Central nervous system 24% (491/2,055) [137]
Prostate 14% (92/658) [135]
Melanoma 16% (104/652) [138]
Uveal melanoma 11% (4/35) [134]